Cargando…

Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug–Drug Interaction Studies?

Detalles Bibliográficos
Autores principales:	Dauki, Anees M., Hsueh, Chia‐Hsiang, Cherala, Ganesh, Othman, Ahmed A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540494/ https://www.ncbi.nlm.nih.gov/pubmed/35687738 http://dx.doi.org/10.1002/cpt.2650

Ejemplares similares

The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
por: Gámez, Beatriz, et al.
Publicado: (2021)

Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
por: Landmark, Cecilie Johannessen, et al.
Publicado: (2008)

Perspective on model‐informed drug development
por: Lesko, Lawrence J.
Publicado: (2021)

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
por: Raparelli, Valeria, et al.
Publicado: (2020)

Model Informed Drug Development and Regulation in China: Challenges and Opportunities
por: Li, Li, et al.
Publicado: (2019)

Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study
por: Lee, Su Jin, et al.
Publicado: (2019)

A Holistic and Integrative Approach for Advancing Model‐Informed Drug Development
por: Madabushi, Rajanikanth, et al.
Publicado: (2019)

Model Informed Drug Development: Collaboration Through A Common Framework
por: Anziano, Richard J., et al.
Publicado: (2020)

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma
por: Campbell, Belinda A., et al.
Publicado: (2020)

The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials
por: Thorlund, Kristian, et al.
Publicado: (2023)

Endpoints in Heart Failure Drug Development
por: Hussain, Aliza, et al.
Publicado: (2022)

PDUFA VI: It Is Time to Unleash the Full Potential of Model‐Informed Drug Development
por: Jain, Lokesh, et al.
Publicado: (2018)

Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce
por: Ayton, Lauren N., et al.
Publicado: (2020)

Ziritaxestat Drug–Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition
por: Helmer, Eric, et al.
Publicado: (2022)

Hypersensitive reactions to local dental anesthetics and patient information: critical review of a drug leaflet
por: Simonet, Daniel
Publicado: (2011)

Learn–confirm in model‐informed drug development: Assessing an immunogenicity quantitative systems pharmacology platform
por: Franssen, Linnea C., et al.
Publicado: (2022)

Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need
por: Jin, Pengfei, et al.
Publicado: (2021)

Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies
por: Li, Yimei, et al.
Publicado: (2022)

Overview of Biomarkers and Surrogate Endpoints in Drug Development
por: Wagner, John A.
Publicado: (2002)

Molecular interaction networks and drug development: Novel approach to drug target identification and drug repositioning
por: Loscalzo, Joseph
Publicado: (2022)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation
por: Kanate, Abraham S., et al.
Publicado: (2019)

Is it time to include oxygen needs as an endpoint in clinical trials in patients with fibrosing interstitial lung disease? If so, how?
por: Aronson, Kerri, et al.
Publicado: (2023)

Age-old wisdom concerning cell-based therapies with added knowledge in the stem cell era: our perspectives
por: Preethy, Senthilkumar, et al.
Publicado: (2013)

The pK(a) Distribution of Drugs: Application to Drug Discovery
por: Manallack, David T.
Publicado: (2007)

Industrial Perspective on the Benefits Realized From the FDA’s Model‐Informed Drug Development Paired Meeting Pilot Program
por: Galluppi, Gerald R., et al.
Publicado: (2021)

Study design considerations to assess the impact of potential drug–drug interactions in first‐in‐human studies in oncology drug development
por: Subramaniam, Sriram, et al.
Publicado: (2023)

An open science pathway for drug marketing authorization—Registered drug approval
por: Naudet, Florian, et al.
Publicado: (2021)

Visualizing classification of drugs used in psychotic disorders: A ‘subway map’ representing mechanisms, established classes and informal categories
por: Zhou, Crystal, et al.
Publicado: (2022)

Antifungal Drug Repurposing
por: Kim, Jong H., et al.
Publicado: (2020)

New Insights into Impaired Muscle Glycogen Synthesis: More a Problem of Muscle Contractility Than of Glucose Tolerance
por: Groop, Leif, et al.
Publicado: (2008)

Drug Selection and Information: Some Recommendations from the World Health Organization
por: Herxheimer, Andrew
Publicado: (1993)

Opportunities and Challenges of Using Big Data to Detect Drug‐Drug Interaction Risk
por: Quinney, Sara K.
Publicado: (2019)

Informative noncompliance in endpoint trials
por: Snapinn, Steven M, et al.
Publicado: (2004)

Conflicting information from the Food and Drug Administration: Missed opportunity to lead standards for safe and effective medical artificial intelligence solutions
por: Hernandez-Boussard, Tina, et al.
Publicado: (2021)

Target Engagement Analysis and Link to Pharmacodynamic Endpoint for a Novel Class of CNS-penetrant and Efficacious p38α MAPK Inhibitors
por: Bachstetter, Adam D., et al.
Publicado: (2014)

Drugging SUMOylation for neuroprotection and oncotherapy
por: Bernstock, Joshua D., et al.
Publicado: (2018)

Paramagnetic NMR in drug discovery
por: Softley, Charlotte A., et al.
Publicado: (2020)

Drugs, sleep, and the addicted brain
por: Valentino, Rita J., et al.
Publicado: (2019)

Amorphous Drug-Polymer Salts
por: Yao, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lvsr4c4u6egknvacco99dd5lu6